• syte

  Participated · Seed · Sep 2024

  syte develops a B2B SaaS platform that aggregates and analyses real-estate data in real time, covering property searches, construction potential, project cost calculations, and energy-efficiency metrics. By layering artificial intelligence on a broad set of property datasets, the company aims to help industry stakeholders digitise workflows and reduce the carbon footprint of the built environment. syte plans to use newly raised capital to further develop its AI data platform and accelerate its mission to digitise and decarbonise the real-estate sector. Beyond equity financing, the company also secured €800K for its “ENERsyte” initiative under the “Grüne Gründungen.NRW” funding competition, adding non-dilutive resources for product development. The platform is positioned for banks, estate agents, developers, and planners seeking faster, data-driven decisions. No public operating metrics or revenue figures were disclosed. syte is led by CEO Matthias Zühlke and CTO David Nellessen.

• VisionHealth

  Led · Equity · Feb 2021

  VisionHealth, founded in 2017 and led by CEO Dr. Sabine Haeussermann, develops digital therapeutic support for respiratory diseases. The company focuses on improving inhaled drug therapy through its Kata® digital therapeutic, which uses augmented reality and the smartphone camera to provide immediate feedback and correction. VisionHealth develops solutions in cooperation with research institutions, selected industry partners, medical experts and IT specialists. The product aims to enable sustainable improvements to existing standard therapies for patients with chronic lung diseases like asthma and COPD. The company intends to use new funding to finance extended COPD and asthma studies and to prepare the market for Kata®. Planned next steps include pursuing EU and U.S. regulatory approval and a commercial launch of the Kata app in Germany and select European markets. VisionHealth GmbH develops digital therapy support for inhalation therapy aimed at improving treatment of chronic respiratory diseases. Its core product, the Kata app, is a medical device that assists and optimizes patients' drug inhalation therapy. The company works with research institutions, industry partners, medical experts and IT experts to create its solutions. Founded in 2017 and based in Garching, Germany, VisionHealth plans to complete regulatory approval of Kata as a Digital Health Application by BfArM under the German Digital Health Care Act (DVG). It intends to use the recent financing to run a health economic trial and complete the approval process to enable permanent reimbursement by German health insurers. The company plans to enter the German market and generate revenue by licensing Kata to pharmaceutical and medtech companies.

No current team members are available.